Astarloa Pharm is developing the high-tech vaccines against SARS-CoV-2 to protect all of us. Orbolocks immunization programm consist of three legs to activate the full spectrum of a smooth immune response to the SARS-CoV-2.
In the process of Orbioiodine® researching his remarkable adjuvant qualities were discovered. As an adjuvant it does not harm the human body unlike most substances used in pharmacology and as a vaccine-adjuvantes. This allowed the company to launch partnership vaccine-project under Orbolocks-Medigen during the coronavirus pandemic, which help vaccinated more than 800,000 people in the Indian Pacific region. The effectiveness of the vaccine in the pandemic was 78 percent.
We made TCCI (triple-system) of SARS-CoV-2 immunization:
1st leg: Orbolocks Primavacc ®
Orbolocks Primavacc ® is "classic" vaccine based on viral inactivation. SARS-CoV-2 s-protein was modified with PL amino acids to strengthen the newmade protein. 2P modification is well-proven method of intervention into Sf9 cells, which form s-protein and to program with it cell membranes. Vaccine has single-shot compulsory program to achieve basic immunity.
Orbolocks Primavacc Advantages:
Interim Phase 1&2 data suggests a well tolerated vaccine with no significant safety issues observed to date. So far we can confirm:
1 shot = 270 days of protection
No serious adverse events
Minimal local/systemic adverse events after shot
2-8°C storage and distribution means no special cold-chain requirements, existing vaccine infrastructure could be used for distribution, even in resource-limited settings.
2nd & 3rd leg (easy boosters): Orbolocks Revacc ® & Orbolocks Sprayvacc ®
Orbolocks vaccines production based on platform technology. This will allow a more systematic approach to vaccination by regulating the load on the immune system at different stages of immunization. Our studies have shown that such a systematic approach to vaccination of the population, including the elderly, induces a stable immune response with repeated doses for three or more years. Antibody levels are recalled to their initial peak following each boost, regardless of the time interval since the last dose. This will remain especially important in an environment where the field has not yet determined the durability of immunity from COVID-19 vaccines, and where we may face a seasonal recurrence of COVID-19, as we see annually with influenza.
Rapid installation to Mutations
We have strong potential to respond rapidly as needed to changes in the SARS-CoV-2 virus. In fact, we successfully mastered technology of rapid response for mutations using developments one of our partner company for AFD (Apthous fever disease) virus mutations.
Orbolocks vaccines also allow for the inclusion and presentation of multiple epitopes to elicit both B-cell (antibody) and T-cell (cellular) responses without enhancing COVID-19 disease. SARS-CoV-2 vaccines currently focus solely on the S-protein. This is a rational target. But in prolonged period (more than 270 days) a single protein may not raise a sufficient or broad enough immune response. Orbolocks Revacc ® & Orbolocks Sprayvacc ® are designed to target also a critical antigen from the S protein (Receptor Binding Domain, RBD) thought to be necessary for viral attachment to human cells plus additional viral epitopes (from other viral structural proteins) designed to promote B-cell and CD8+ T-cell memory responses. SARS-CoV-2 evolution is not linear and need comprehensive approach to immunization without injections under the copier.
Protection shown in AAC hACE2 mice, and lack of immunopathology in lungs
Induces functional antibodies as well as a balanced cellular response (Th1/Th2, with Th1 polarity)
Neutralization of SARS-CoV-2, >100-fold higher than convalescent sera from Covid-19 patients
Inhibition of RBD: hACE2 interactions
Orbolocks Primavacc ® Orbolocks Revacc ® Orbolocks Sprayvacc ® reaches the final investigational phase and will be approved and licensed in primary jurisdiction during 2022
TCCI - Orbolocks Phased Immuization: